Ramani Anup P, Gill Inderbir S, Steinberg Andrew P, Abreu Sidney C, Kilciler Mete, Kaouk Jihad, Desai Mihir
Section of Laparoscopic and Minimally Invasive Surgery, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
J Urol. 2005 Jul;174(1):226-8. doi: 10.1097/01.ju.0000162048.15746.52.
At many centers systemic heparinization is performed during laparoscopic donor nephrectomy because of concerns regarding graft thrombosis. However, no consensus exists in this regard. We evaluated the impact of intraoperative heparin on donor and recipient outcomes.
Between September 2000 and February 2003, 79 consecutive patients underwent laparoscopic live donor left nephrectomy at our institution. They were sequentially divided into 2 groups, that is group 1-the initial 40 patients who intraoperatively received 5,000 IU heparin intravenously and group 2-subsequent patients who did not receive heparin. The 2 groups were well matched demographically. Data were compared using the paired 2-tailed t test.
The 2 donor groups were comparable in regard to mean blood loss (139 vs 179 cc, p = 0.59), intraoperative urine output (1.6 vs 1.6 l, p = 0.74), warm ischemia time (4 vs 4.2 minutes, p = 0.52), operative time (3.5 vs 3.5 hours, p = 0.97), and cold ischemia time (75 vs 82 minutes, p = 0.38). Complications occurred in 1 patient in group 1 (rhabdomyolysis induced acute renal failure) and in 2 in group 2 (chylous ascites and lumbar vein injury, respectively). No graft was lost due to vascular thrombosis in either group. Recipient immediate, early and delayed (6-month) graft function was comparable between the 2 groups. Acute rejection occurred in 5 recipients in group 1 and 1 in group 2. There was 1 recipient death per group at delayed followup.
Routine use of heparin during laparoscopic donor nephrectomy is not necessary. Because of its potential for causing intraoperative or early postoperative hemorrhage, we no longer routinely administer intraoperative heparin during laparoscopic donor nephrectomy at our institution.
由于担心移植肾血栓形成,许多中心在腹腔镜供肾切除术期间进行全身肝素化。然而,在这方面尚未达成共识。我们评估了术中肝素对供体和受体结局的影响。
2000年9月至2003年2月期间,我们机构连续79例患者接受了腹腔镜活体供体左肾切除术。他们被依次分为2组,即第1组——最初的40例患者术中静脉注射5000 IU肝素,第2组——随后未接受肝素的患者。两组在人口统计学上匹配良好。数据使用配对双尾t检验进行比较。
两组供体在平均失血量(139对179 cc,p = 0.59)、术中尿量(1.6对1.6 l,p = 0.74)、热缺血时间(4对4.2分钟,p = 0.52)、手术时间(3.5对3.5小时,p = 0.97)和冷缺血时间(75对82分钟,p = 0.38)方面具有可比性。第1组有1例患者发生并发症(横纹肌溶解诱发急性肾衰竭),第2组有2例(分别为乳糜腹水和腰静脉损伤)。两组均无移植肾因血管血栓形成而丢失。两组受体的即刻、早期和延迟(6个月)移植肾功能具有可比性。第1组有5例受体发生急性排斥反应,第2组有1例。延迟随访时每组各有1例受体死亡。
腹腔镜供肾切除术期间常规使用肝素没有必要。由于其有导致术中或术后早期出血的可能性,我们机构在腹腔镜供肾切除术期间不再常规给予术中肝素。